[Effect of combined therapy with lysosome labilizer and antineoplastic agents with reference to increased effect of mitomycin C by lipoprotein lipase].
D000818:Animals; D003911:Dextrans / Q000008:administration & dosage; D004357:Drug Synergism; D005341:Fibrinolysin / Q000627:therapeutic use; D006801:Humans; D008071:Lipoprotein Lipase / Q000008:administration & dosage*; D008247:Lysosomes / Q000187:drug effects*; D008937:Mitomycins / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*; D012517:Sarcoma, Yoshida / Q000188:drug therapy; D013431:Sulfates / Q000627:therapeutic use
D003911:Dextrans; D008937:Mitomycins; D013431:Sulfates; D008071:Lipoprotein Lipase; D005341:Fibrinolysin